Α Multicenter Retrospective Study Evaluating Brivaracetam in the Treatment of Epilepsies in Clinical Practice
Brivaracetam (BRV) is the latest approved antiepileptic drug. The aim of the study was to evaluate the efficacy and tolerability of BRV in everyday clinical practice. In this retrospective, observational, multicenter study, data from epilepsy patients receiving BRV from January 2018 to July 2019 wer...
Main Authors: | Maria Stefanatou, Eirini Vasileiadou Kapetanou, Vasilios K. Kimiskidis, Vasileios Papaliagkas, Panagiotis Polychronopoulos, Sofia Markoula, Kleoniki Charisiou, Dimitrios Kazis, Anastasia Verentzioti, Panayiotis Patrikelis, Athanasia Alexoudi, Stylianos Gatzonis |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-02-01
|
Series: | Pharmaceuticals |
Subjects: | |
Online Access: | https://www.mdpi.com/1424-8247/14/2/165 |
Similar Items
-
New developments in the management of partial-onset epilepsy: role of brivaracetam
by: Coppola G, et al.
Published: (2017-03-01) -
Brivaracetam in the Treatment of Patients with Epilepsy—First Clinical Experiences
by: Felix Zahnert, et al.
Published: (2018-02-01) -
A review of the pharmacology and clinical efficacy of brivaracetam
by: Klein P, et al.
Published: (2018-01-01) -
Efficacy and tolerability of brivaracetam in the treatment of epilepsy: literature review and own experience
by: O. A. Pylaeva, et al.
Published: (2018-11-01) -
In vitro antineoplastic effects of brivaracetam and lacosamide on human glioma cells
by: Ambra Rizzo, et al.
Published: (2017-06-01)